In this study, cyclin B1 was a stronger marker of poor prognosis than proliferation markers cyclin A or Ki67 (among chemotherapy-naive patients the RR for poor survival in univariate analysis was 2.47 for cyclin A and 1.90 for Ki67) and the risk for poor survival was also stronger than that has been previously reported for Ki67 or cyclin A. In multivariate analysis among chemotherapy-naive patients, high cyclin B1 was almost as strong predictor of poor OS as HER2 and PR status, or even tumour grade, and it predicted poor MFS more powerfully than HER2 and PR status or tumour grade. This evidence concerns the gene PGR and neoplasm.